Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Hold” from Analysts

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) has been assigned an average recommendation of “Hold” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $34.50.

A number of research analysts have recently weighed in on SLN shares. Jefferies Financial Group restated a “buy” rating on shares of Silence Therapeutics in a report on Thursday. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Thursday, January 22nd.

Silence Therapeutics Stock Performance

NASDAQ:SLN opened at $6.23 on Monday. The company has a market capitalization of $294.27 million, a P/E ratio of -3.33 and a beta of 1.32. The stock’s 50 day moving average price is $5.32 and its 200 day moving average price is $5.76. Silence Therapeutics has a 52 week low of $1.97 and a 52 week high of $7.78.

Silence Therapeutics (NASDAQ:SLN) last posted its earnings results on Thursday, March 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.07. The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $2.19 million. Silence Therapeutics had a negative net margin of 15,851.88% and a negative return on equity of 101.71%. As a group, sell-side analysts forecast that Silence Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SLN. Nantahala Capital Management LLC lifted its holdings in Silence Therapeutics by 48.0% in the 4th quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock worth $9,378,000 after purchasing an additional 500,000 shares during the last quarter. Millennium Management LLC grew its holdings in Silence Therapeutics by 121.0% during the fourth quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock valued at $4,010,000 after purchasing an additional 361,080 shares during the last quarter. Ishara Investments LP bought a new position in shares of Silence Therapeutics in the fourth quarter valued at approximately $1,459,000. Seven Fleet Capital Management LP bought a new position in shares of Silence Therapeutics in the fourth quarter valued at approximately $897,000. Finally, Opaleye Management Inc. acquired a new stake in shares of Silence Therapeutics in the fourth quarter worth $480,000. 98.73% of the stock is owned by institutional investors.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.